Hematologic Diseases
170
15
26
97
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Treatment Research
20 treatments under study, led by Cyclophosphamide
Published Results
23 trials with published results (14%)
Research Leaders
20 sponsors active, led by National Heart, Lung, and Blood Institute (NHLBI)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.9%
10 terminated out of 170 trials
90.7%
+4.0% vs benchmark
14%
23 trials in Phase 3/4
24%
23 of 97 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 97 completed trials
Clinical Trials (170)
Gulf Long-Term Follow-Up Study
HEME Home Transfusion Program
Data Collection of Standard Care and Evaluation of NHLBI Patients and Donors
Hypnosis and Virtual Reality in Bone Marrow Examination
Naturopathic-pharmacological Consultation in Hematology
Study on the Clinical Efficacy of Teclistamab and Talquetamab
Clinical Study of Combined Platelet Transfusion
Immersive Virtual Reality Applied to Therapeutic Physical Exercise in Cellular Therapy
Visual and Auditory Distraction for the Relief of Pain and Anxiety
Pacritinib With Aza for Upfront Myelodysplastic Syndrome
Muscle Dysfunction in Patients With Haematological Diseases
A Long-term Follow-up Study in Participants Who Received CTX001
Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
The Impact of the Practice of Touch-massage on the Anxiety of Patients With Hematological Disorders Hospitalized in a Protective Environment, a Randomized, Controlled Study
The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease
Bleeding Events Before vs After Lowering Departmental Platelet Transfusion Trigger
Autologous Testicular Tissue Transplantation
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
Research Network
Common Treatments
- Cyclophosphamide7
- Busulfan6
- Ctx0014
- Rd1302 Cell Infusion4
- Fludarabine4
Active Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)23
- Universitaire Ziekenhuizen KU Leuven5
- Copenhagen University Hospital, Rigshospitalet5
- Vertex Pharmaceuticals Inc.4
- Stanford University4
Top Investigators
Department of Clinical Therapeutics, School of Medicine, National Kapodistrian University of Athens (NKUA)
UZ Leuven Gasthuisberg
Bnai Zion Medical Center
First Affiliated Hospital of Zhejiang University
National Heart, Lung, and Blood Institute (NHLBI)
Related Conditions
- Neoplasms15
- Leukemia14
- Multiple Myeloma12
- Anemia Sickle Cell10
- Hemoglobinopathies10